|
|||||
|
|
Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer |
|
| Authors: | Verweij, J. Wanders, J. Nielsen, A. L. Pavlidis, N. Calabresi, F. Huinink, W. ten Bokkel Bruntsch, U. Piccart, M. Franklin, H. Kaye, S. B. On behalf of the EORTC Early Clinical Trials Group, |
| Affiliation: | 1Rotterdam Cancer Institute Rotterdam 2EORTC New Drug Development Office Amsterdam, The Netherlands 3University Hospital of Copenhagen Herlev, Denmark 4University of loannina loannina, Greece 5Instituto Regina Elena Rome, Italy 6Netherlands Cancer Institute Amsterdam, The Netherlands 75 Medizinische Klinik Nurnberg Germany 8Institute Jules Bordet Brussels, Belgium 9Beatson Oncology Centre Western Infirmary, Glasgow, U.K. |
| Abstract: | PURPOSE:: To test the antitumor activity of Elsamitrucin in metastaticcancer of the breast, colon and rectum, non-small cell lungand ovary. PATIENTS AND METHODS:: Eligibility required histologically proven cancer. Patientswith colorectal or non-small cell lung cancer could not havereceived prior chemotherapy. Patients were entered if WHO PSwas  2 and organ functions were normal. Treatment consisted ofElsamitrucin 25 mg/m2/week given as a 510 min infusionfor at least 36 weekly doses. RESULTS:: One hundred and five patients entered the studies, 97 were eligible,94 are evaluable for toxicity and 75 for response. Toxicitymainly consisted of mild nausea/vomiting, and less frequentlyreversible hepatotoxicity and malaise. No objective responseswere seen. CONCLUSION:: Elsamitrucin at this dose and schedule is not an active drugin metastatic breast cancer, colorectal cancer, non-small celllung cancer or ovarian cancer. Elsamitrucin, phase II, breast, colorectum, nonsmall cell lung, ovary |
| Keywords: | |
| 本文献已被 Oxford 等数据库收录！ | |